Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.68 |
| ▸ | F2 | P00734 | 2/20 | 0.68 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.68 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226910 | 1.00 | F10 (0.68) | F10F2KLKB1PLAT | |
| SCHEMBL5222416 | 0.86 | F10 (0.67) | F10F2KLKB1 | |
| SCHEMBL5222405 | 0.86 | F10 (0.67) | F10F2KLKB1 | |
| Gw813893 SCHEMBL16439470 | 0.81 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL4559370 | 0.81 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL23752149 | 0.81 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL6219768 | 0.81 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL675586 | 0.81 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL675587 | 0.81 | F10 (1.00) | F10F2KLKB1PLAT | |
| SCHEMBL5222296 | 0.81 | F10 (0.68) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444201-B1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2007-09-12 | — | — | EP | disclosed |
| US-7179835-B2 | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-20 | — | — | US | disclosed |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| EP-1444201-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003043981-A1 | 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | SERPINC1, F11, SERPINE1 | F10 17/4885F2 5/4885KLKB1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.